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 Wilcoxon). Combining mAb together did not increase cell bin-
ding inhibition. The contribution of CD44 could not be assessed 
because the addition of HA to the assay did not generate 
reproducible results. None of the mAbs, nor HA (from 1 ug to 
1 mg/ml) affected T cell proliferation in the absence of MSC, 
or impaired MSC-induced T cell inhibition, thus indicating that 
integrin-induced cell-cell interaction was not the effector of 
the inhibition. Moreover experiments performed with transwell 
systems showed that T cell transmigration under MSC was not 
associated with inhibition as long as the compartment where 
the cells landed after transmigration was voluminous.
In conclusion, the binding of activated T cells to MSC is only par-
tially mediated by beta-2 intergrins and seems not associated 
with MSC regulatory function. However cell-cell interactions 
may favor the action of soluble inhibitory effectors synthesized 
by MSC.
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Background: Tacrolimus (TAC) suppress T-cell activation by 
inhibiting calcineurin (CN). CN activity was assessed in the 
allogeneic recipients who were treated with TAC for graft-
versus-host disease (GVHD) prophylaxis to investigate whe-
ther CN activity was increased in patients with severe acute 
GVHD.
Methods: CN activity was analyzed in 10 consecutive patients 
who underwent allogeneic stem cell transplantation (SCT). TAC 
was administered at a dose of 0.03 mg/kg intravenously from 
day-1 to +21. TAC levels and CN activity was assessed on day-
1 before TAC administration and days 0, +3, +7, +14, and +21. 
Target TAC concentration (15-20 ng/ml) was maintained during 
the current study.
Results: The cumulative incidence of acute GVHD (74.1% 
vs. 60.3%, p=0.888) and severe chronic GVHD (22.5% vs. 
33.3%, p=0.539) were not different between high and low TAC 
trough levels. CN activity on day-1 was 0.12±0.09 nmol and 
had decreased from baseline level (0.29±0.15 nmol, p<0.001). 
There was no correlation between CN activity and TAC concen-
trations (r2=0.024). CN activity was steady-state during post-
transplant day+0 to +14 regardless of acute GVHD, CN activity 
on day+21 for those with grade 2-4 acute GVHD showed higher 
CN activity (0.18±0.04 nmol) compared to those without grade 
2-4 acute GVHD (0.14±0.05 nmol, p=0.462). Cumulative inci-
dence of acute GVHD (40% vs. 80%, p=0.248) and chronic 
GVHD (20% vs. 70%, p=0.464) between low and high CN acti-
vity group were not signiÞ cantly different.
Conclusion: Maintaining target TAC trough level did not cor-
relate with the development of GVHD in allogeneic recipients. 
Although GVHD was higher for the high CN activity on day+21, 
this pilot study failed to demonstrate signiÞ cant difference due 
to small sample size. However, the patients manifesting GVHD 
with high CN activity on post-transplant D+21 may need to be 
treated with other kinds of immunosuppressive agent regardless 
of drug level.
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To elucidate the mechanisms behind graft versus tumor effect 
(GVT) and graft versus host disease (GVH), our laboratory 
adapted a murine model of allogeneic bone marrow (BM) 
transplantation using B10.D2 donor mice and Balb/cJ recipient 
mice that were inoculated with MOPC-315.BM myeloma cells. 
Balb/cJ recipient mice were intravenously (IV) injected with 
2,5x105 luciferase transfected MOPC-315.BM cells. At day 30 
after inoculation, 6 mice received an autologous transplantation 
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(Balb/cJ cells) and 8 mice received an allogeneic transplanta-
tion (B10.D2 cells) by IV injection of 10x106 BM cells and 70x106 
spleen cells. Prior to transplantation, both groups of mice were 
irradiated with 6 Gy. Tumor development was followed by 
measuring their bio-luminescence using VIVOVISION IVIS 200 
(Xenogen). Immune responses were followed by taking blood 
samples before transplantation (day -2), and at days 7 and 19 
after transplantation, analysing lymphocyte counts and NK, NKT 
and T-cell subpopulations. When mice showed signs of para-
plegia or signs of GVH disease, they were sacriÞ ed and ana-
lysed for immune activation and regulation in different organs 
(blood, spleen, lymph nodes, thymus and bone marrow). In vivo 
imaging showed disappearance of the luciferase signal in 7 of 
the 8 allografted mice. All the mice that received an autologous 
transplantation developed myeloma disease. The recovery of 
myeloma diseased mice by this allogeneic transplantation could 
be attributed to an immune graft versus myeloma effect. Further 
analysis of the cellular subpopulations at sacriÞ ce (Allografted 
vs Autografted mice) showed a decrease in regulatory T cells 
[% of CD4: Blood 5,5±2,6 vs 18,4±4,4 (p=1,6x10-5); Spleen 
20,6±8 vs 24,7±4,7 (p=0,29); BM 10,9±6.5 vs 48,1±6,4 
(p=1,79x10-7)] and activation (CD69) of both CD4 T lymphocy-
tes [% of CD4: Blood 45,4±14,5 vs 14,6±8,1 (p=0,0006); Spleen 
44,9±8,9 vs 23,1±5,5 (p=0,0002); BM 60,4±14,4 vs 46,2±5,6 
(p=0,04)] and CD8 T lymphocytes [% of CD8: Blood 51,6±14,8 
vs 12,3±6,7 (p=6,2x10-5); Spleen 46±7,9 vs 11,2±2,7 (p=2,5x
10-7); BM 69,6±9,6 vs 37,6±10,9 (p=8,1x10-5)]. The same trends 
were observed in simply allografted control mice.
This model will be used for studying the mechanisms behind 
graft versus tumour effect (antigen mismatches, activation of 
T cell subpopulations) and the effects of immune suppressors 
(e.g. rapamycin) on the graft versus tumour effect.
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Background: Umbilical cord blood (CB) transplantation is known 
to be associated with delayed and defective immune reconsti-
tution, in part because recent thymic emigrants (RTEs), have 
limited intrinsic survival. Interleukin-7 (IL-7) has been reported 
to increase the initial recovery of the graft-derived T-cells com-
partment. The aim of this study was to investigate CB-derived 
T-cell survival and to deÞ ne a minimal effective dose of recom-
binant human IL-7 (rIL-7), considering that in addition to its 
anti-apoptotic effect, IL-7 may enhance immune reactions that 
occur in the host, including acute GVHD.
Methods: Fifteen CB were obtained after normal-term delivery, 
using the same procedure as for CB banking. T cells were iso-
lated within 12 hours by negative magnetic bead sorting and 
cultured for 2 weeks either directly or after being frozen. Unsti-
mulated T cell cultures were conducted in parallel in medium 
(RPMI supplemented with 10% normal AB serum) alone or 
supplemented with a range of rIL-7concentrations added either 
only once at day 0 (100 to 1000 pg/mL) or every day (10 to 100 
pg/mL). Cell viability was assessed by ß ow cytometric scatter 
analysis and staining with 3,3’-dihexyloxacarbocyanine iodide 
[DiOC6(3)] and propidium iodide.
Results: In basic culture conditions, the majority of T cells had died 
over 2 weeks. There was heterogeneity in cell survival, with 2% to 
50% viables T cells (median 15%) at day 6 of culture. Interestin-
gly, the same intrinsic characteristics of survival were observed in 
T cells that underwent beforehand a freezing- thawing procedure.
In cultures supplemented with rIL-7, we conÞ rmed the efÞ cacy 
of rIL-7 in maintaining CB T cell survival. A minimal dose of 
25 pg/mL added daily was sufÞ cient to induce the prolonged 
survival of CB T cells, with more than 95% of viable cells at day 
6. Noteworthy, these concentrations allowed prolonged survival 
of CD T cells without inducing any cell proliferation, as shown 
by the absence of CFSE dilution. Similar results were observed 
comparing CB cells that had been frozen or not.
Conclusion: Repeated low-doses of rIL-7 are required to pre-
serve the survival capacity of CB T cells without inducing their 
proliferation. These results could represent a framework for cli-
nical studies aiming at improving T cell reconstitution following 
allogeneic CB transplantation. Repeated administration of low-
doses of rIL-7 might be especially useful in patients with low 
serum levels of IL-7 after conditioning.
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Objectives: Chemotherapy treatment related toxicities are com-
mon among children undergoing Haemopoietic Stem Cell Trans-
plantation (HSCT). Gastrointestinal complications, such as oral 
and intestinal mucositis, are related to increased risk of severe 
infections and increased mortality. The objective of this study was 
to investigate intestinal structural, functional and inß ammatory 
markers after treatment with busulfan (Bu) and cyclophospha-
mide (Cy) in a piglet model of chemotherapy-induced mucositis.
Methods: Piglets were allocated to receive either 4 d of Bu plus 2 
days of Cy (1.6 and 60 mg/kg/d, respectively, Bu-Cy group, n=9) 
or saline (controls, n=8) intravenously. After 6 days chemothe-
rapy or saline, pigs were kept for another 5 days until when inte-
stinal samples were collected for histomorphometry (villus height 
and crypt depth), activity of six brush border enzymes (disac-
charidases, peptidases) and tissue levels of cytokines (IL-8, 
IL-1beta and TNF-alfa) in the proximal and distal intestine.
Results: Bu-Cy pigs had 40% shorter villi in the proximal inte-
stine, relative to controls (p<0.01) while no difference was seen 
in the distal intestine. Crypt depths were smaller in both proxi-
mal and distal intestine (18-24%, p<0.05). Likewise, the activity 
of the brush border enzymes in the proximal intestine (sucrase, 
ApA, ApN and DPPIV) were 30-50% lower in Bu-Cy pigs 
compared with controls pigs (p<0.01 for all) while in the distal 
intestine only sucrase was lower in Bu-Cy pigs (p<0.05). No 
differences were found for maltase and lactase. IL-8 were 40% 
higher (p<0.05) in the proximal intestine while TNF-alfa levels 
were 50% higher in the distal intestine of Bu-Cy pigs (p<0.05). 
No difference was found for IL-1-beta.
Conclusion: The Bu-Cy treatment resulted in structural damage 
and reduced functions, especially in the proximal part of the 
small intestine within 5 days after the 6 days treatment protocol. 
A faster enterocyte turnover in the proximal versus the distal 
intestine may explain that chemotherapy induces more marked 
effects proximally. The associated increases in tissue IL-8 and 
TNF-alfa levels reß ect local bacteria-stimulated inß ammatory 
reactions. These may accelerate damage and prime the tis-
sue to later development of graft versus host diseas following 
infusion of a transplantat. Pharmacological and dietary factors 
should be investigated as means to reduce the immediate inte-
stinal effects of Bu-Cy treatment.
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Background: Fludarabine-Cytabarine-Melphalan combination 
(FLAM) is a novel combination chemotherapy which theore-
tically has the advantage of being able to provide Central 
